Clinical bottom line
The gut microbiome plays a critical role in modulating the efficacy and toxicity of cancer immunotherapy, particularly immune checkpoint inhibitors. Specific microbial compositions and diversity patterns correlate with improved treatment responses and reduced immune-related adverse events. While microbiome modulation represents a promising adjunct to enhance immunotherapy outcomes, clinical implementation awaits further validation through prospective trials and standardized microbiome profiling.
What the evidence shows
Bolte et al. (2025) provide a comprehensive overview of pharmacomicrobiomics, detailing how gut microbial communities influence immunomodulation and cancer therapy efficacy. They highlight that certain bacterial taxa, such as Akkermansia muciniphila and Bifidobacterium species, are associated with enhanced anti-PD-1/PD-L1 responses across multiple tumor types.
Nobels et al. (2025) review the multifaceted role of the gut microbiome in tumorigenesis and therapy, emphasizing its impact on systemic immunity and tumor microenvironment modulation. Their synthesis underscores that microbiome diversity and functional capacity can predict immunotherapy outcomes.
Zuo et al. (2024) focus on colorectal cancer, demonstrating that patients with favorable gut microbiome profiles exhibit improved responses to checkpoint blockade. They also discuss microbiome-driven mechanisms such as antigen presentation enhancement and T-cell activation.
Nawal Harsh et al. (2025) explore the gut microbiome’s influence on anti-PD-1 immunotherapy in melanoma patients, identifying microbial signatures predictive of response and immune-related toxicity. Their findings support microbiome profiling as a potential biomarker.
Bourgi et al. (2025) examine bladder cancer, suggesting that microbiome composition may explain variability in immunotherapy efficacy and proposing microbiome-targeted interventions to overcome resistance.
Szczyrek et al. (2021) provide a nutritional perspective, reviewing how diet-induced microbiome alterations can modulate immunotherapy response, highlighting the potential for dietary interventions.
Mishra et al. (2027) discuss emerging strategies to modulate the gut microbiome, including probiotics, prebiotics, antibiotics, and fecal microbiota transplantation, aiming to enhance immunotherapy efficacy.
Caveats and uncertainty
Most evidence derives from observational studies with limited sample sizes and heterogeneous methodologies.
Causal relationships between specific microbes and immunotherapy outcomes remain to be definitively established.
Microbiome composition is influenced by multiple confounders including diet, antibiotics, and comorbidities, complicating interpretation.
Standardized protocols for microbiome sampling, sequencing, and analysis are lacking, limiting reproducibility.
Interventional trials testing microbiome modulation strategies are in early phases, with safety and efficacy yet to be confirmed.
How this may change practice
Microbiome profiling could become part of pretreatment assessment to identify patients likely to benefit from immunotherapy.
Adjunctive microbiome modulation—via diet, probiotics, or fecal transplantation—may enhance response rates and mitigate toxicity.
Oncology teams should consider antibiotic stewardship to preserve beneficial microbiota during immunotherapy.
Integration of microbiome data with other biomarkers may improve personalized immunotherapy strategies.
Ongoing clinical trials will inform evidence-based guidelines for microbiome-targeted interventions in cancer care.